Medulloblastoma, Childhood Clinical Trial
Official title:
Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children
The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.
Medulloblastoma (medulloblastoma, MB) is the most common intracranial malignant tumor in children, accounting for 20% of all central nervous system tumors in children, seriously affecting the quality of life and life span of children. Based on a retrospective analysis of previous MB cases in our center, we found that the clinical prognosis of previous MB patients in our center was worse than that in foreign countries, with an overall five-year survival rate of about 65%, and nearly 30% of the patients had tumor recurrence and metastasis within 2 years after the operation, and the prognosis was poor. We analyzed the possible reasons as follows: (1) the compliance to radiotherapy and chemotherapy in children with MB in our center was poor, and some of the patients only completed radiotherapy and had poor compliance with chemotherapy; (2) due to the lack of family doctor system, the tumor of the newly diagnosed patients was huge, which seriously affected the important brain function and clinical prognosis; (3) the patients were not followed up strictly and regularly after operation to monitor tumor recurrence, which led to poor treatment effect after recurrence. (4) the unified treatment standard has not been formed yet, and the treatment mode for patients is complex. As the largest neurosurgery and pediatric neurosurgery center in China, the center intends to prospectively establish a high-quality homogeneous MB observation cohort in children, make use of the center's case resources and biological sample processing advantages, and carry out accurate treatment research on children's MB through regular follow-up and systematic management of the clinical cohort. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04167618 -
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03288168 -
Children's and Adolescents' Medulloblastoma Molecular Subgroups in China
|
||
| Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 | |
| Recruiting |
NCT04174820 -
Child's Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
|
||
| Completed |
NCT04860934 -
Dual Task Training On Children With Ataxia After Medulloblastoma Resection
|
N/A | |
| Active, not recruiting |
NCT06193759 -
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
|
Phase 1 | |
| Suspended |
NCT03904862 -
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01697514 -
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
|
Phase 1 | |
| Recruiting |
NCT05230758 -
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
|
Phase 3 | |
| Completed |
NCT02238899 -
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
|
N/A | |
| Recruiting |
NCT05057702 -
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
|
N/A | |
| Recruiting |
NCT04185038 -
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
|
Phase 1 | |
| Completed |
NCT04528316 -
Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor
|
N/A | |
| Terminated |
NCT02624388 -
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
|
Phase 2 |